和黄医药(00013.HK) 公布,经过与国家医保局的医保续约,沃瑞沙(ORPATHYS,赛沃替尼)将继续获纳入自2025年1月1日起生效的新版《国家基本医疗保险、工伤保险和生育保险药品目录》,并维持与现行两年期协议相同的条款。
沃瑞沙于2021年6月在中国获附条件批准,用于治疗特定的MET外显子14跳跃突变的非小细胞肺癌患者。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-28 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.